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Motoko Maekawa, Tomoko Toyota, Kazuo Yamada, Eiji Hattori, Tetsuo Ohnishi,
Manabu Toyoshima, Hiroshi Ujike, Toshiya Inada, Hiroshi Kunugi, Norio Ozaki,
Shinichiro Nanko, Kazuhiko Nakamura, Norio Mori, Shigenobu Kanba, Nakao Iwata,
Tadafumi Kato, and Takeo YoshikawaBackground: Genome-wide association studies have successfully identified several common variants showing robust association with
schizophrenia. However, individually, these variants only produce a weak effect. To identify genetic variants with larger effect sizes,
increasing attention is now being paid to uncommon and rare variants.
Methods: From the 1000 Genomes Project data, we selected 47 candidate single nucleotide variants (SNVs), which were: 1) uncommon
(minor allele frequency 5%); 2) Asian-specific; 3) missense, nonsense, or splice site variants predicted to be damaging; and 4) located
in candidate genes for schizophrenia and bipolar disorder. We examined their association with schizophrenia, using a Japanese case-
control cohort (2012 cases and 2781 control subjects). Additional meta-analysis was performed using genotyping data from
independent Han-Chinese case-control (333 cases and 369 control subjects) and family samples (9 trios and 284 quads).
Results: We identified disease association of a missense variant in GRIN3A (p.R480G, rs149729514, p ¼ .00042, odds ratio [OR] ¼ 1.58),
encoding a subunit of the N-methyl-D-aspartate type glutamate receptor, with study-wide significance (threshold p ¼ .0012). This
association was supported by meta-analysis (combined p ¼ 3.3  105, OR ¼ 1.61). Nominally significant association was observed in
missense variants from FAAH, DNMT1, MYO18B, and CFB, with ORs of risk alleles ranging from 1.41 to 2.35.
Conclusions: The identified SNVs, particularly the GRIN3A R480G variant, are good candidates for further replication studies and
functional evaluation. The results of this study indicate that association analyses focusing on uncommon and rare SNVs are a promising
way to discover risk variants with larger effects.Key Words: Bipolar disorder, CFB, DNMT1, FAAH, GRIN3A,
MYO18B, NR3A, rare variants
G
enome-wide association studies (GWAS), which typically
examine millions of common (minor allele frequency
[MAF] 5%) single nucleotide polymorphisms (SNPs),
have been highly successful in identifying genetic variants
reproducibly associated with complex human traits (1). Several
large-scale GWAS for schizophrenia have been conducted (2–8)
and have provided important findings, for example: 1) the
identification of genetic loci such as 6p21-p22.1 (major histo-
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cance level (p  5  108 ); 2) the proposal of a genetic
architecture for schizophrenia, which is most likely extremely
polygenic, involving possibly thousands of common SNPs con-
ferring a disease risk; and 3) support for genetic overlap between
schizophrenia and bipolar disorder, based on the overall profiles
of common SNPs and top hit genes, such as CACNA1C.
As is the case for most complex diseases, the risk-conferring
common SNPs identified so far only have small effect sizes, with
odds ratios (OR) predominately ranging from 1.1 to 1.3. Although
a recent study indicated that overall profiles of common SNPs
could explain a significant part of the variation in liability to
schizophrenia (9), single common SNPs have minimal predictive
value and it is uncertain whether they contribute greatly to
unraveling the pathogenetic mechanisms that lead to schizo-
phrenia. To discover genetic variants with larger effect sizes,
emphasis has shifted toward analyzing uncommon (MAF 5%)
or rare (MAF 1% or .1%) single nucleotide variants (SNVs),
especially those that directly affect protein coding.
Along with a growing interest in rare variants, recent advances
in sequencing technology, particularly the emergence of the
next-generation sequencing techniques, have enabled us to
obtain large volumes of sequence data in a rapid and cost-
effective manner. A number of novel and interesting findings
have been reported in pioneering works that utilized next-
generation sequencing. In studies of psychiatric and neurodeve-
lopmental diseases, involvement of pathogenic de novo SNVs in
intellectual disability, autism spectrum disorder, and schizophre-
nia has been demonstrated (10–18). In studies of nonpsychiatric
complex diseases, for example, sick sinus syndrome (19), inflam-
matory bowel disease (20), and celiac disease (21), uncommonBIOL PSYCHIATRY 2013;73:532–539
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by resequencing and fine-mapping analyses of loci detected by
GWAS. In a resequencing analysis of candidate genes for
impulsivity, an uncommon nonsense variant in HTR2B is reported
to be associated with psychiatric diseases marked by impulsivity
(22). The HTR2B nonsense variant reported in that study was
exclusive to Finns, highlighting the point that uncommon
variants are often population-specific. Therefore, intensive studies
using non-Caucasian samples provide an opportunity to discover
novel, uncommon risk variants with larger effect sizes that cannot
be detected in the Caucasian population, the most extensively
investigated population in genetic studies to date.
In addition to analysis of de novo variants, fine mapping of
loci previously identified in GWAS, and resequencing of targeted
candidate regions, we can now utilize dense catalogs of human
genetic variations, including uncommon SNVs created by next-
generation sequencing projects, such as the 1000 Genomes
Project (23) and the Exome Sequencing Project (24), albeit that
the latter was confined to European American and African
American samples. Uncommon SNVs in these projects were
found in seemingly healthy subjects, contrary to extremely rare
variants that are robustly associated with psychiatric disorders,
such as autism spectrum disorder and schizophrenia, and have
been identified exclusively in case samples. However, these
uncommon SNVs could represent another class of variants that
go some way to provide an explanation for the as yet undiscov-
ered genes responsible for disease heritability. Association
analysis of these variants is another promising strategy for
identifying genetic risks for common diseases.
In this study, we selected candidate SNVs from the 1000
Genomes Project data, focusing on uncommon, population-
specific, and protein-damaging variants. A total of 47 candidate
SNVs satisfied the criteria of being: 1) uncommon; 2) missense,
nonsense, or splice site variants predicted to be damaging; 3)
Asian-specific; and 4) located in candidate genes for schizophre-
nia and bipolar disorder. These SNVs were subjected to associa-
tion analysis using a Japanese case-control cohort, consisting of
2012 patients with schizophrenia and 2781 healthy control
subjects. We also performed meta-analysis using genotyping
data from an independent Han-Chinese case-control set
(results from 333 cases and 369 control subjects, previously
reported by another group) and family samples (9 trios and
284 quads, genotyped by our laboratory for this study), to
analyze the most significantly associated SNV in a Japanese
case-control study.Methods and Materials
Subjects
We used a Japanese case-control sample, consisting of 2012
unrelated patients with schizophrenia (1111 men, 901 women;
mean age 48.1  14.4 years) and 2781 control subjects (1197
men, 1584 women; mean age 43.7  14.4 years). We also used
865 samples from unrelated Japanese patients with bipolar
disorder (425 men, 440 women; mean age 50.2  14.4 years;
584 with bipolar I disorder, 276 with bipolar II disorder, and 5
with schizoaffective disorder bipolar type) for additional analysis.
Samples from bipolar patients and some of the control partici-
pants were recruited through the Collaborative Study of Mood
Disorders consortium (25). All participants were of Japanese
origin and were recruited from the Hondo area of Japan.
Populations in the Hondo area are known to fall into a singlegenetic cluster (26). In our previous analysis using a subset of the
same participants, it was shown that Pr(K ¼ 1) (probability that
the number of populations present in the sample ¼ 1 [27]) was
larger than .99 (28,29) and l (genomic control factor [30]) was
1.074 (31). These data indicated a negligible population stratifica-
tion effect in our Japanese samples. All patients had a consensual
diagnosis of schizophrenia, according to DSM-IV criteria, from at
least two experienced psychiatrists. All healthy control subjects
were psychiatrically screened in unstructured interviews. All
control subjects and patients gave informed, written consent to
participate in the study after being provided with and receiving
an explanation of study protocols and objectives.
We also genotyped Han-Chinese samples from mainland
China and Taiwan, consisting of 293 schizophrenia pedigrees
(1163 subjects: 9 trios and 284 quads, offspring were all affected)
(32). This sample set was collected by the National Institute of
Mental Health initiative (http://nimhgenetics.org/). Diagnoses of
these samples were made using the Diagnostic Interview for
Genetic Studies (33) and the Family Interview for Genetic Studies
(34), based on DSM-IV-Text Revision or DSM-IV criteria.
In the meta-analysis, genotyping data collated in a report by
Shen et al. (35) was included. In that study, case-control samples of
Han-Chinese in Taiwan (333 cases and 369 control subjects) were
used. All patients in this cohort were diagnosed by senior
psychiatrists using the Structured Clinical Interview for DSM-IV-TR
Axis I Disorders. Exclusion criteria included psychosis due to general
medical conditions, substance-related psychosis, and mood disorder
with psychotic features. Mental status of control participants was
evaluated by senior psychiatrists in diagnostic interviews.
This study was approved by the ethics committees of all
participating institutes.
Selection of Single Nucleotide Variants
We selected candidate SNVs from the 1000 Genome Project
data, released on December 16, 2010 (23). In this version,
22,891,767 SNVs with PASS flags for quality controls were
included. Among them, 11,573,027 SNVs were detectable in
Asians, of which 1,911,710 were Asian-specific. From these, we
selected variants using the following criteria: 1) missense or splice
site variants; 2) variants located within the 1568 genes registered
in SZGene (36) or the Bipolar Disorder Gene Database (37)
(accessed in January 2011); 3) variant calls with a Phred
score 10, indicating a call accuracy of 90%; 4) variants with
MAF 5% in Asians; and 5) variants with MAF 0 and 5% in
the Japanese population. A total of 308 variants remained after
the selections. These included one variant located at an essential
splice site. There were no nonsense variants. To narrow down the
list further, we evaluated functionality of the remaining missense
variants, using conservation scores from 46 vertebrate species
(phyloP score, collected from the University of California Santa
Cruz (UCSC) genome browser [38] [University of California, Santa
Cruz, California]) and two programs predicting the impact of
missense variants (PolyPhen2 [39] and SIFT [40]). Finally, 47 SNVs,
comprising one essential splice site variant and 46 putatively
functional missense variants (a phyloP score 2, predicted to be
probably or possibly damaging by PolyPhen2 and predicted to
be damaging by SIFT) were selected. The process of SNV
selection is summarized in Table 1.
Genotyping
Genotyping of Japanese case-control samples was performed
using the iPlex Assay on the Sequenom MassARRAY plat-
form (SEQUENOM, San Diego, California), according to thewww.sobp.org/journal
Table 1. Number of SNVs Passing Each Filtering Criterion
Filtering Criteria
Number of SNVs
Remaining
With PASS Flag 22,891,767
In Asian 11,573,027
Only in Asian 1,911,710
In Coding Regions (UCSC Genes hg19) 21,679
Nonsense, Missense, or Splice Site 14,305
In SZGene or Bipolar Disorder Gene Database
(January 2011, 1568 Genes)
1195
Phred Score 10 392
MAF in Asian .05 308
MAF in Japanese 0  and  .05
phyloP 2 and Damaging in PolyPhen2 and SIFT
Prediction or in Essential Splice Sites (or
Nonsense)
47 (one splice site
and 46 missense
variants)
MAF, minor allele frequency; SNV, single nucleotide variant; UCSC,
University of California Santa Cruz.
534 BIOL PSYCHIATRY 2013;73:532–539 A. Takata et al.manufacturer’s instructions. When primers for the iPlex assay
could not be designed or genotyping scatter plots were not well
clustered, we first tested the candidate base positions for variant
alleles using Sanger sequencing. For this test, we used 384
samples consisting of 128 samples each of patients with schizo-
phrenia, patients with bipolar disorder, and controls subjects.
These were a part of the samples described in the Subjects
section. Single nucleotide variants validated by this analysis were
then genotyped using the TaqMan SNP genotyping assay
(Applied Biosystems, Grand Island, New York). To evaluate the
genotyping accuracy of the multiplex iPlex Assays, we included
two previously analyzed SNPs (rs2279381 and rs3763627 [41] and
unpublished data [Kazuo Yamada, MD, PhD, et al.]) that had been
genotyped using the TaqMan assay. Genotyping of Chinese
schizophrenia pedigree samples collected by the National Insti-
tute of Mental Health initiative was performed using the
TaqMan assay.Quality Control and Statistical Analyses
Quality control of genotyping data was performed using the
following exclusion criteria: 1) samples with a call rate
of 80%; 2) SNVs with a call rate of 98%; 3) SNVs showing
significant deviation from Hardy-Weinberg equilibrium (HWE)
in control samples (p  .001); and 4) SNVs showing a signifi-
cant difference of success rate (that is, the proportion of
individuals with successful genotype data) between cases
and control subjects (p  .001). Allelic association was ana-
lyzed using Fisher’s exact test. For analysis of the CACNA1F
S671C variant (rs143938580) located on chromosome X, one
allele per male sample and two alleles per female sample were
counted. Analyses of deviation from HWE, success rate for
genotyping, allelic association, and the transmission disequili-
brium test (TDT) were performed using PLINK software (version
1.0.7) (42). McNemar’s exact test for TDT was performed using
the exact22 package for R (43) (http://www.r-project.org/).
Meta-analysis of case-control and TDT data sets and evaluation
of sample heterogeneity were performed using the case-
control and TDT meta-analysis package, catmap for R (44).
The Q statistic (45) calculated by catmap was used for
the assessment of heterogeneity among data sets. Post
hoc calculations of statistical power were performed usingwww.sobp.org/journalthe Genetic Power Calculator (http://pngu.mgh.harvard.edu/
purcell/gpc/) (46) with the multiplicative model.Results
Allelic Association Analyses
The results of Japanese case-control allelic association ana-
lyses are shown in Table 2, while detailed information about
selected SNVs and the filtering criteria are shown in Table 1. The
GRIN3A R480G variant (rs149729514) was most significantly
associated with schizophrenia (p ¼ .00042, OR ¼ 1.58; two-
tailed Fisher’s exact test). From the number of SNVs whose
association could be tested in this study (43 SNVs), we defined a
study-wide significance threshold as .0012 (¼ .05/43). Association
of the GRIN3A R480G variant (p ¼ .00042) was more significant
than this study-wide significance threshold. Nominal association
was observed for FAAH A356V (rs77101686, p ¼ .010, OR ¼ .71),
DNMT1 G876R (rs62621087, p ¼ .031, OR ¼ 1.53), MYO18B E559K
(rs117243697, p ¼ .032, OR ¼ 2.35), and CFB R576H variants
(rs117314762, p ¼ .046, OR ¼ .7).
From 47 selected SNVs, we observed no variant alleles for three
base positions in our population (ADRA1A R376H: rs140512348, FAT1
T3326A: no rs number, and HDAC9 G32R: rs79608746). One SNV
(DDX39B R259C: rs145191873) failed quality control, due to a low call
rate. Genotypic distribution of the CD36 P90S variant (rs75326924) in
control subjects deviated from HWE, with nominal significance (p ¼
.010). Significant difference in the success rate of genotyping was not
observed for any SNVs. The consistency between multiplex iPLEX
genotyping in this study and TaqMan genotyping in our previous
experiments was 99.9% for rs2279381 and 100% for rs3763627,
proving the accuracy of genotyping by the iPLEX Assay.
Replication Analysis and Meta-Analysis of the GRIN3A R480G
Variant
To test the validity of association between GRIN3A R480G
variant and schizophrenia, we performed replication and meta-
analyses, using two sets of data from independent samples.
In 2009, Shen et al. (35) resequenced GRIN3A using samples from
the Han-Chinese population in Taiwan, consisting of 333 patients
with schizophrenia and 369 control subjects. They detected the
R480G variant as an uncommon SNV, along with a nonsignificant
overrepresentation of the G allele (Table 3, p ¼ .145, OR ¼ 1.52,
one-tailed Fisher’s exact test). Although it has been demonstrated
that the genetic clusters generated by Japanese and Han-Chinese
populations are different from each other (26), MAFs of the GRIN3A
R480G variant in our Japanese samples and their Han-Chinese
samples from Taiwan were similar (2.1% in Japanese control
subjects and 1.9% in Han-Chinese control subjects).
We also analyzed Han-Chinese pedigree samples, consisting of
9 trios and 284 quads with affected offspring. We successfully
genotyped 565 out of 577 offspring and their parents and observed
a nominally significant overtransmission of the G allele (Table 3,
p ¼ .036, OR ¼ 1.92, one-tailed McNemar’s exact test).
Combining the three data sets, meta-analysis further sup-
ported association between the R480G variant and schizophrenia
(Table 3 and Fig. 1, combined p ¼ 3.3  105, OR ¼ 1.61). In this
meta-analysis, we included all probands from trio and quad
samples. This result did not change significantly when we
randomly selected one proband from each pedigree (combined
p ¼ 6.5  105, OR ¼ 1.60). As there was no significant
heterogeneity among three data sets (Q statistic p ¼ .85), the
fixed-effect model was applied for meta-analysis.
Table 2. Results of the Allelic Association Analysis
First Gene SNV
MAF
p
Chr Position dbSNP ID Appeareda Reference Variant Symbol Property PhyloP PolyPhen2 SIFT Cases Control Subjects Value OR
1 19,071,356 rs57227966 Build 129 G A PAX7 R484H 5.68 Probably damaging Damagingb .95 1.28 .14 .74
1 46,874,246 rs77101686 Build 131 C T FAAH A356V 4.18 Probably damaging Damaging 2.19 3.06 .010c .71
2 216,248,878 rs147655202 Build 134 C T FN1 V214M 2.57 Probably damaging Damaging 1.61 1.51 .74 1.07
3 58,135,711 rs141559684 Build 134 G A FLNB A2107T 6.42 Probably damaging Damaging .90 .91 1.00 .99
3 58,140,563 rs138327769 Build 134 C G FLNB S2258C 4.46 Probably damaging Damaging .12 .18 .61 .69
3 170,732,328 rs1800572 Build 89 C T SLC2A2 V101I 5.86 Probably damaging Damaging 3.37 2.68 .050 1.27
4 187,531,047 Not registered / T C FAT1 T3326A 4.95 Probably damaging Damaging Variant allele was not observed
5 131,325,201 rs3763118 Build 107 C T ACSL6 V126M 3.27 Probably damaging Damaging .55 .89 .070 .62
5 168,201,351 rs2288792 Build 100 C T SLIT3 R395Q 6.1 Probably damaging Damaging 1.00 1.12 .61 .89
6 31,503,104 rs145191873 Build 134 G A DDX39B R259C 2.21 Probably damaging Damagingb QC failed
6 31,914,306 rs117314762 Build 132 G A CFB R576H 2.5 Probably damaging Damaging 1.27 1.80 .046c .70
6 87,725,674 rs3828741 Build 107 G A HTR1E A208T 5.47 Probably damaging Damaging 1.11 1.11 1.00 1.00
6 123,101,544 rs2279381 Build 100 C T FABP7 T61M 3.39 Probably damaging Damaging 2.62 2.76 .70 .95
6 132,910,485 rs80078646 Build 131 T A TAAR5 D114V 3.36 Probably damaging Damaging 3.30 4.08 .055 .80
6 135,644,371 rs148000791 Build 134 T C AHI1 E536G 4.86 Possibly damaging Damaging 4.29 4.24 .92 1.01
6 152,614,868 rs80265744 Build 131 C T SYNE1 R480H 2.08 Probably damaging Damagingb .30 .29 1.00 1.04
6 155,458,738 rs116960376 Build 132 C T TIAM2 T541M 4.26 Probably damaging Damaging 4.07 4.68 .16 .86
7 18,535,896 rs79608746 Build 131 G A HDAC9 G32R 5.76 Possibly damaging Damaging Variant allele was not observed
7 21,892,164 rs150631721 Build 134 C T DNAH11 A3666V 4.22 Probably damaging Damaging .60 .76 .38 .79
7 48,412,084 rs143050255 Build 134 A T ABCA13 Q3708L 2.63 Probably damaging Damaging 1.19 1.51 .21 .78
7 80,286,003 rs75326924 Build 131 C T CD36 P90S 5.03 Probably damaging Damaging 4.14 4.79 .15 .86
7 99,366,093 rs12721627 Build 121 G C CYP3A4 T185S 3.28 Possibly damaging Damaging 1.64 2.09 .13 .78
8 16,853,208 rs3793405 Build 107 C G FGF20 G116R 6.27 Probably damaging Damaging 3.33 3.28 .91 1.02
8 22,421,982 rs77246845 Build 107 C T SORBS3 P255L 2.92 Probably damaging Damaging .78 .51 .11 1.54
8 22,426,701 rs3758036 Build 131 C T SORBS3 P449L 5.49 Probably damaging Damaging 2.57 2.48 .79 1.04
8 23,301,426 rs150919990 Build 134 G A ENTPD4 P202S 3.84 Probably damaging Damaging .97 1.26 .20 .77
8 26,627,940 rs140512348 Build 134 C T ADRA1A R376H 2.74 Probably damaging Damagingb Variant allele was not observed
8 133,634,908 rs76147813 Build 131 G T LRRC6 P288H 2.05 Possibly damaging Damaging 5.16 4.85 .50 1.07
9 104,433,256 rs149729514 Build 134 G C GRIN3A R480G 4.16 Probably damaging Damaging 3.28 2.11 .00042c 1.58
10 55,663,053 rs149478475 Build 134 C T PCDH15 G1156R 4.72 Probably damaging Damaging .43 .47 .88 .90
10 61,840,324 rs74777754 Build 131 C T ANK3 R593H 4.36 Probably damaging Damagingb 2.45 1.96 .12 1.26
10 121,286,832 rs117042762 Build 132 C T RGS10 V44M 2.11 Probably damaging Damaging 1.05 1.34 .22 .78
12 56,495,023 rs2271188 Build 100 G A ERBB3 R1127H 5.13 Probably damaging Damagingb 1.52 1.81 .30 .84
12 70,932,745 rs138916804 Build 134 G A PTPRB P1725L 4.51 Possibly damaging Damaging 1.20 1.11 .70 1.08
12 123,022,996 rs75373025 Build 131 A G KNTC1 T121A 3.69 Probably damaging Damagingb .65 .54 .50 1.20
12 123,028,739 rs61751320 Build 129 A G KNTC1 T198A 3.91 Probably damaging Damagingb 1.71 2.05 .25 .83
13 99,356,584 rs2274827 Build 100 G A SLC15A1 R459C 3.23 Possibly damaging Damaging 2.66 2.72 .90 .98
13 103,343,179 rs140948695 Build 134 G T METTL21C A89E 3.9 Probably damaging Damaging .28 .24 .69 1.17
17 67,079,352 rs149614799 Build 134 C T ABCA6 Splice site 5.28 – – .87 .82 .82 1.07
18 21,353,474 rs76572574 Build 131 G C LAMA3 G399A 5.15 Probably damaging Damagingb 2.50 2.30 .54 1.09
18 70,417,304 rs118113391 Build 132 C T NETO1 V512I 5.8 Possibly damaging Damagingb 2.24 2.20 .94 1.02
19 10,259,654 rs62621087 Build 129 C T DNMT1 G876R 3.7 Probably damaging Damaging 1.44 .95 .031c 1.53
21 37,417,981 rs145926295 Build 134 C T SETD4 V209M 3.56 Probably damaging Damaging .61 .51 .57 1.19
22 26,166,934 rs117243697 Build 132 G A MYO18B E559K 4.15 Probably damaging Damaging .42 .18 .032c 2.35
22 26,706,697 rs117917851 Build 132 G A SEZ6L E526K 3.29 Possibly damaging Damaging 2.13 2.05 .83 1.04
22 42,294,751 rs17848351 Build 123 G C SREBF2 V902L 3.94 Possibly damaging Damaging 1.49 1.69 .46 .88
X 49,079,494 rs143938580 Build 134 G C CACNA1F S671C 4.86 Probably damaging Damaging 1.38 1.54 .62 .89
Chr, chromosome; dbSNP, Single Nucleotide Polymorphism database; MAF, minor allele frequency; OR, odds ratio; QC, quality control; SNV, single nucleotide variant.
aThe release version of dbSNP in which each variant appeared first. dbSNP later than the Build129 contains data from the 1000 Genomes project.
bPrediction with low confidence.
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Figure 1. Forest plots of odds ratios (OR) and their 95% confidence
intervals (CI) for individual studies and meta-analysis.
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www.sobp.org/journalAssociation Analysis of the GRIN3A R480G Variant with
Bipolar Disorder
There is accumulating evidence to support the existence of
overlap in the genetic susceptibility to schizophrenia and bipolar
disorder (4,47,48). To test whether GRIN3A R480G shows positive
association with bipolar disorder, we genotyped samples from
Japanese bipolar disorder patients (865 samples). While the G
allele, which was overrepresented in schizophrenia, was more
frequent in bipolar case samples, we did not observe significant
association (p = .138, MAF in cases = 2.72%, OR = 1.3; two-tailed
Fisher’s exact test). Statistical power obtained from the sample
size of bipolar cases and control subjects was 33% for nominal
significance (a = .05). Association analysis using combined
Japanese schizophrenia and bipolar disorder cases and control
subjects (2877 cases and 2781 control subjects) showed study-
wide significant association (p = .00077, Bonferroni-corrected p =
.033. OR = 1.50), but the association was slightly less significant
than that observed with schizophrenia.Discussion
In this study, we performed association analyses of uncom-
mon, putatively functional, and Asian-specific SNVs with schizo-
phrenia. We observed five significantly associated SNVs with ORs
ranging from 1.41 to 2.35. Among them, the GRIN3A R480G
variant showed the strongest association with study-wide sig-
nificance (p = .00042, Bonferroni-corrected p = .018). Positive
association of the GRIN3A R480G variant was observed in
independent Han-Chinese pedigree samples (p = .036). Meta-
analysis using these data sets and published data from Han-
Chinese case-control samples collected in Taiwan further sup-
ported this association (combined p = 3.3  105).
On the other hand, we observed no significant association of
the GRIN3A R480G variant with bipolar disorder. While calculation
of statistical power indicated that the sample size of our bipolar
cases was not sufficient to appropriately assess association, it is
A. Takata et al. BIOL PSYCHIATRY 2013;73:532–539 537possible that this variant may be more relevant to schizophrenia
than bipolar disorder.
The GRIN3A R480G variant was not detected in Caucasian and
African American populations (23,24) and thus far seems Asian-
specific. However, if aberrant GRIN3A function, driven by genomic
variations in this gene, does contribute to the pathogenesis of
schizophrenia, other risk variants within this gene could be
identified in non-Asian populations (and if so, those variants
might be non-Asian specific in some cases).
The association signals in GRIN3A have not been detected
with genome-wide significance in large-scale GWAS conducted
so far. This is not surprising, considering the sample sizes used for
the reported GWAS and the MAF and OR of the GRIN3A R480G
variant observed in this study. For example, if there is a common
SNP with 10%, 25%, or 50% MAF in complete linkage disequili-
brium (LD) with the R480G variant, the OR of this common SNP
would be 1.13, 1.05, and 1.03, respectively, and the number of
cases required for 80% power should be 29,012, 83,979, and
248,882, respectively.
Therefore, the sample sizes used in the reported Chinese (7,8)
and Japanese (49,50) GWAS have not been sufficient to identify
common marker SNPs in LD with the GRIN3A R480G variant. Even
the largest Caucasian GWAS to date (6) would not have enough
power to detect marker SNPs, if other risk-contributing SNVs
existed in GRIN3A did not generate ORs and/or MAFs much larger
than those of the GRIN3A R480G variant. This point clearly
indicates the advantage of direct genotyping of disease risk-
contributing SNVs, especially in studies aiming to identify risk
variants with moderate effect sizes, using medium-sized samples.
GRIN3A encodes the NR3A subunit of the N-methyl-D-aspartate
type glutamate receptor (NMDAR). Involvement of NMDAR
hypofunction in the pathophysiology of schizophrenia was first
proposed, on the observation that NMDAR antagonists, such
as phencyclidine, ketamine, and MK801, induced psychiatric
abnormalities that mimic both positive and negative symptoms
of schizophrenia (51). The NMDAR hypofunction theory is sup-
ported by various lines of evidence from pharmacologic, genetic,
postmortem histopathologic, and brain imaging studies (52).
N-methyl-D-aspartate type glutamate receptor is a hetero-
meric tetramer protein, composed of two obligate NR1 subunits
and two subunits from the NR2 or NR3 families. NR3A acts in a
dominant-negative manner to suppress NMDAR activity (53,54).
NR3A-containing NMDARs display reduced calcium ions (Ca2)
permeability and low sensitivity to magnesium ion (Mg2)
blockade (55,56).
In postmortem brains of patients with schizophrenia,
increased GRIN3A expression in layer V of the dorsolateral
prefrontal cortex (57), along with decreased spine density in
the same region (58,59), were reported. Removal of NR3A
increases spine density (56) and promotes synapse maturation
and memory consolidation (60,61). Male NR3A knockout mice
show increased prepulse inhibition, a measure of sensorimotor
gating, which is impaired in schizophrenia and other neuropsy-
chiatric disorders (62). These findings collectively suggest the
involvement of aberrant, possibly enhanced, GRIN3A function in
the pathophysiology of schizophrenia, while also implying that
the R480G variant of GRIN3A promotes a gain of function.
Other significantly associated SNVs are located in FAAH,
DNMT1, MYO18B, and CFB. FAAH encodes the integral membrane
enzyme fatty acid amide hydrolase. Another missense variant in
this gene (P129T) was reported to be associated with drug
addiction (63–65). DNMT1 encodes DNA (cytosine-5-)-methyl-
transferase 1, which plays an important role in maintainingmethylation patterns in the mammalian genome (66). MYO18B
encodes an unconventional myosin, myosin-XVIIIb. This gene
harbors rs5761163, which is one of the most significantly
associated SNPs in GWAS, conducted by the International
Schizophrenia Consortium (4). It is noteworthy that the MYO18B
E559K variant and rs5761163 are in complete LD in the 1000
Genomes Project data. CFB encodes complement factor B, a
component of the complement system. This gene resides in the
major histocompatibility complex class III region on chromosome
6p21.3, a locus associated with schizophrenia, with genome-wide
significance (3–6,8). Nevertheless, association of these variants
was only nominal and the significant probability of false positivity
should be recognized.
To interpret the results of this study more appropriately, two
main limitations need to be considered. First, the number of SNVs
analyzed in this study was limited. As a selection criterion for SNVs in
this study was location in candidate disease genes, it was not
surprising to find association of missense variants in promising
genes, such as GRIN3A. Given the poor replication status of candidate
gene association studies for schizophrenia and other psychiatric
diseases, more comprehensive and hypothesis-free analyses, parti-
cularly genome-wide association studies of uncommon and puta-
tively functional variants are warranted, especially if we are to
uncover new genes. Second, the statistical power obtained from
our samples was insufficient for testing association of rare and
uncommon variants with a stringent threshold of significance. While
we applied study-wide significance (p  .0012) defined by the
number of investigated SNVs in this study, genome-wide significance
(p  5  108 ) is needed to demonstrate concrete association. Post
hoc statistical power for analysis of the GRIN3A R480G variant,
calculated from the overall allele counts used in meta-analysis, was
99.3% for nominal significance (a ¼ .05) and 88.5% for study-wide
significance (a ¼ .0012) but only 15.6% for genome-wide signifi-
cance (a ¼ 5  108 ). Moreover, if we consider our Japanese cohort
as a sample set for discovery, the statistical power that can be
obtained from both sets of Han-Chinese samples for replication are
62.7, 17.0, and .1% for a levels of .05, .0012, and 5  108,
respectively. To corroborate the association observed in this study,
analyses using further independent samples should be conducted.
As that has already been demonstrated in genetic studies of
other complex diseases, analysis of uncommon protein-
damaging SNVs is a valid method of isolating risk variants with
larger effects. The identification of study-wide significant associa-
tion and the observed ORs of associated SNVs in this study would
also support this strategy. More comprehensive genome-wide
analysis and replication studies are necessary to overcome the
limitations of this study, and they will undoubtedly provide
further solid and informative biological insight into the patho-
physiology of schizophrenia. This caveat aside, our finding that
this putatively functional variant of NR3A, a subunit of the
NMDAR, showed significant association with schizophrenia paves
the way for functional characterization of this mutation in animal
models and sets the stage for the discovery of other uncommon
disease-associated variants.This study was supported by RIKEN Brain Science Institute
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“Development of biomarker candidates for social behavior” project,
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